The understanding of cancer's genetic basis has revolutionized oncology, paving the way for personalized medicine.  Early research, focusing on chromosomal abnormalities like the Philadelphia chromosome in chronic myeloid leukemia (CML), provided foundational insights into the role of specific genetic alterations in driving uncontrolled cell proliferation.  This understanding evolved with the advent of high-throughput sequencing technologies, enabling the identification of numerous oncogenes, tumor suppressor genes, and DNA repair genes implicated in various cancers.  The discovery of driver mutations, which confer a selective growth advantage to cancer cells, has been particularly impactful.  This knowledge fuels the development of targeted therapies, such as tyrosine kinase inhibitors (TKIs) for CML, which specifically target the aberrant protein products of these driver mutations.  Advances in genomics further allow for the stratification of patients based on their unique tumor profiles, enabling the prediction of treatment response and the selection of the most effective therapeutic strategy. This personalized approach contrasts sharply with earlier, broadly applied chemotherapies and offers the potential for improved efficacy and reduced toxicity, ultimately enhancing cancer patient outcomes.  Ongoing research continues to refine our understanding of the complex interplay of genetic and epigenetic factors in cancer development, promising further advancements in personalized cancer care.